

CEAT LIMITED RPG House 463, Dr. Annie Besant Road, Worli, Mumbai - 400030, India \$ 91 22 24930621 \$ customercare@ceat.com @ www.ceat.com CIN: L25100MH1958PLC011041

June 25, 2025

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 Security Code: 500878 National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai 400 051 Symbol: CEATLTD NCD symbol: CL25, CL26

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 and 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is continuation to our letter(s) dated October 17, 2024, March 3, 2025, and June 20, 2025. Pursuant to Regulations 30 of the SEBI Listing Regulations, this is to inform you that the Finance and Banking Committee (FBC) of the Board of Directors of the Company at its meeting held on June 25, 2025 which commenced at 5:00 pm IST and concluded at 5:25 pm IST, *inter-alia* consented, approved and/or noted the following:

 Issuance of unsecured Non-Convertible Debentures ('NCD') pursuant to enabling approval of the shareholders vide Annual General Meeting held on August 29, 2024, for general corporate purposes *inter-alia*, for financing of the on-going capital expenditure for expansion of capacity, reduction of overall interest and finance cost as well as for general purposes including the restructuring/replacement of high cost debt and working capital requirements, for an aggregate amount not exceeding Rs. 500 crores in one or more tranches, on a private placement basis.

This is an addition to the existing NCDs of Rs. 250 crores already issued by the Company.

- Capital infusion upto Rs. 400 crores (equivalent LKR) in one or more tranches in CEAT OHT LANKA (PRIVATE) LIMITED, Sri Lanka a wholly owned subsidiary of the Company through equity and/or preference shares.
- Availing of credit facility of upto Rs. 1,000 crores for business purposes in one or more tranches.

Details required as per the relevant SEBI Circular are enclosed herewith as Annexures.

It is requested to take the same on record.

Thanking you,

Yours faithfully, For **CEAT Limited**

(Gaurav Tongia) Company Secretary

Encl. A/a



CEAT LIMITED RPG House 463, Dr. Annie Besant Road, Worli, Mumbai - 400030, India \$\science\$ 91 22 24930621 \$\vec{1}\$ customercare@ceat.com @ www.ceat.com CIN: L25100MH1958PLC011041

Annexure(s)

Proposed Issuance of NCDs

Sr. No	Particulars	Details
1.	Type of securities proposed to be issued	Rated, Listed, Unsecured Redeemable Non- Convertible Debentures
2.	Type of issuance	Private placement
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued*	NCDs of Face Value of Rs. 10,00,000 each, aggregating up to Rs. 500 Crores in aggregate, one or more tranches.
4.	Size of the issue*	Up to Rs. 500 crores in one or more tranches
5.	Whether proposed to be listed? If yes, name of the stock exchange(s)	Yes. Proposed to be listed on Wholesale Debt Market Segment of National Stock Exchange of India Limited
6.	Tenure of the instrument - date of allotment and date of maturity*	Tenure not exceeding 5 years. Further details would be submitted upon allotment.
7.	Coupon/interest offered, schedule of payment of coupon/interest and principal*	Coupon/interest offered: Fixed Rate The Coupon rate will be determined basis bidding at Electronic Book Provider (EBP) Platform of NSE. Relevant details will then be submitted, accordingly Schedule of payment of coupon/interest: Annual Interest. Payment Schedule payment of principal: Bullet repayment at the end of respective maturity period.
8.	Charge/security, if any, created over the assets	Not applicable as NCDs are unsecured
9.	Special right/interest/privileges attached to the instrument and changes thereof	Not applicable
10.	Delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal	
11.	Details of any letters or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and/or the assets along with its comments thereon, if any	



CEAT LIMITED RPG House 463, Dr. Annie Besant Road, Worli, Mumbai - 400030, India \$ 91 22 24930621 \$ customercare@ceat.com @ www.ceat.com CIN: L25100MH1958PLC011041

12.	Details of redemption of preference shares indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures*	Bullet repayment at the end of the respective maturity period.
13.	Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not applicable

*Aforesaid are indicative terms for proposed issuance of NCDs to be effected in due course, subject to evolving market developments.





Sr. No	Particulars	Details
1.	Name of the target entity, details in	CEAT OHT Lanka (Private) Limited ('WOS'), Sri Lanka
	brief such as size, turnover etc.	Capital infusion upto INR 400 crores (equivalent LKR) in one or more tranches in the form of equity and/or preference shares.
		Size/Turnover: Not applicable as recently incorporated
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The said entity is a related party of the Company. Further except, to the extent of being a subsidiary, the Promoter / promoter group/ group companies of CEAT Limited, do not have any interest in the said entity.
3.	Industry to which the entity being acquired belongs	Automotive Tyres, Tubes and other ancillary products/activities
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The capital infusion is intended to partly fund the ongoing acquisition of Camso brand's Off-Highway construction equipment tyre and tracks business as intimated to the Exchanges on December 6, 2024.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None, however relevant filings required as per the applicable provisions
6.	Indicative time period for completion of the acquisition	Proposed capital infusion is subscription to the capital of WOS
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration
8.	Cost of acquisition and/ or the price at which the shares are acquired	Par value of shares
9.	Percentage of shareholding / control acquired and / or number of shares acquired	100% of shares held by the Company
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable as this is an intimation about capital infusion into the recently incorporated WOS which is in the same line of business and is yet to commence commercial operations.

Proposed Capital infusion into Wholly Owned Subsidiary